基本信息:
- 专利标题： NOVEL FGFR3 FUSION PRODUCT
- 专利标题（中）：新生儿FGFR3-FUSIONSPRODUKT
- 申请号：EP13757006.5 申请日：2013-03-07
- 公开(公告)号：EP2824181A1 公开(公告)日：2015-01-14
- 发明人： SUZUKI, Atsushi , ASAUMI, Makoto , TSUNOYAMA, Kazuhisa , NISHIMURA, Kouichi , MORINAKA, Akifumi , YAMAUCHI, Tomohiro , YOSHINO, Masayasu , YOSHIZAKI, Hiroaki
- 申请人： Astellas Pharma Inc.
- 申请人地址： 5-1, Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 JP
- 专利权人： Astellas Pharma Inc.
- 当前专利权人： Astellas Pharma Inc.
- 当前专利权人地址： 5-1, Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 JP
- 代理机构： Hoffmann Eitle
- 优先权： JP2012052147 20120308; JP2012195451 20120905; JP2012280325 20121221
- 国际公布： WO2013133351 20130912
- 主分类号： C12N15/09
- IPC分类号： C12N15/09 ; A61K45/00 ; A61P35/00 ; C12Q1/68 ; G01N33/53
摘要：
[Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer.
[Means for Solution] The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.
摘要（中）：
[Means for Solution] The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.
本发明旨在阐明多核苷酸作为癌症的新型负责基因，其目的在于提供一种检测多核苷酸的方法和由该多核苷酸编码的多肽以及检测试剂盒，探针组和用于 检测。 本发明还旨在提供一种治疗癌症的药物组合物。 [解决方案]该方法检测由FGFR3基因的一部分和TACC3基因的一部分或融合基因编码的融合蛋白构成的融合基因。 引物组，探针组或检测试剂盒包含有义引物和由编码FGFR3的部分设计的探针组和由编码TACC3的部分设计的反义引物和探针组。 由于多肽的抑制剂表现出抗肿瘤效果，因此提供了用于治疗对融合基因或多肽呈阳性的癌症的药物组合物。
公开/授权文献:
- EP2824181B1 NOVEL FGFR3 FUSION PRODUCT 公开/授权日：2018-11-14